Please ensure Javascript is enabled for purposes of website accessibility

Why Novavax Stock Jumped Nearly 10% Today

By Keith Speights - Mar 30, 2020 at 3:14PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A rising stock market and continued excitement over last week's positive clinical results lifted the biotech higher.

What happened

Shares of Novavax (NVAX -2.68%) are soaring today, up 9.6% as of 3:16 p.m. EDT. The nice gain comes as the overall stock market is rallying after President Trump signed the $2.2 trillion Coronavirus Aid, Relief, and Economic Security (CARES) Act passed by a bipartisan vote in both houses of the U.S. Congress over the weekend. Novavax is also continuing to enjoy momentum from its announcement last week of positive results from a late-stage study of flu vaccine NanoFlu.

So what

The old adage that "a rising tide lifts all boats" no doubt applied to Novavax as the stock market moved higher today. However, the more important story for the biotech stock is its big clinical win for NanoFlu.

Healthcare professional holding a syringe and vaccine bottle

Image source: Getty Images.

Novavax's phase 3 clinical study results for NanoFlu should bode well for its chances of FDA approval. The experimental flu vaccine met both of its primary endpoints in the head-to-head study comparing it against Sanofi's Fluzone Quadrivalent. NanoFlu also demonstrated a safety profile similar to Fluzone. 

Now what

The primary thing for investors to watch now is how quickly Novavax can file for FDA approval of NanoFlu. But the company does have at least one other key development to keep your eyes on.

Novavax is one of several drugmakers scrambling to advance an experimental novel coronavirus vaccine to clinical testing. The biotech is currently evaluating multiple nanoparticle-based vaccines and plans to select the most promising candidate to move into a clinical study in humans by May or June.

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novavax, Inc. Stock Quote
Novavax, Inc.
NVAX
$60.27 (-2.68%) $-1.66

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
377%
 
S&P 500 Returns
123%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/07/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.